These Peptides Have the Human Data to Back Them Up
In Part 1 of this series I introduced the peptide conversation — what peptides actually are, why your body is already running on them, and why this field deserves a more rigorous clinical discussion than it is currently receiving in most public forums.
Today I want to move into the evidence.
Specifically — the compounds that have earned serious clinical attention. The ones with peer-reviewed human trial data, regulatory standing in one or more jurisdictions, and an evidence base that has been tested, replicated, and scrutinized at the level the science requires.
This is Category One. And it matters — not just because these compounds are clinically significant, but because they establish the standard against which everything else in the peptide space should be evaluated.
If you understand what validated peptide science looks like, you become significantly better equipped to evaluate the compounds that do not meet that standard. That discernment is what protects you — and what separates a clinical conversation from a marketing one.
What Puts a Compound in Category One
Before naming the specific compounds, it is worth being precise about what the criteria actually are.
Category One compounds have human clinical trial data. Peer-reviewed trials conducted in human subjects, with measurable outcomes, published in indexed scientific journals. This is a meaningfully higher bar than animal research, mechanistic theory, or community reporting.
Several also carry regulatory approval in one or more jurisdictions — most relevantly the FDA in the United States, or equivalent bodies in Europe, Asia, or elsewhere. Regulatory approval does not guarantee a compound is right for every individual or every clinical context. But it does mean the evidence base has been evaluated by an independent body with the mandate and the resources to assess it critically.
These are the compounds where the conversation about clinical application can begin from a defensible scientific foundation. Everything else requires a different and more cautious framing — which we will address in Parts 3 and 4 of this series.
The Compounds
Sermorelin
Sermorelin is a synthetic analogue of growth hormone releasing hormone — the naturally occurring peptide produced by the hypothalamus that signals the pituitary gland to release growth hormone.
It was FDA-approved for the treatment of growth hormone deficiency in children and has been used off-label in adults in the context of age-related growth hormone decline. Its mechanism is physiological rather than pharmacological — it works by stimulating the body's own growth hormone production rather than introducing exogenous growth hormone directly. This distinction matters clinically because it preserves the natural pulsatile pattern of growth hormone secretion and the feedback mechanisms that regulate it.
Human clinical data on Sermorelin supports its effects on growth hormone secretion, lean body mass, body fat reduction, sleep architecture, and recovery. Research published in the Journal of Clinical Endocrinology and Metabolism demonstrated that Sermorelin administration in growth hormone-deficient adults produced significant improvements in body composition, exercise capacity, and quality of life measures.
The sleep architecture connection is particularly relevant to the work I do. Growth hormone is released predominantly during deep slow-wave sleep. Sermorelin's ability to support endogenous growth hormone production has downstream implications for sleep quality, recovery, and the cellular repair processes that deep sleep enables.
Tesamorelin
Tesamorelin is a stabilized analogue of growth hormone releasing hormone, developed specifically for clinical application in HIV-associated lipodystrophy — the accumulation of visceral fat around the abdomen associated with HIV infection and antiretroviral therapy.
It carries FDA approval for this indication and has a substantial human clinical trial base supporting its effects on visceral adiposity and metabolic parameters. The EVIDENCE trial, a large randomized controlled study, demonstrated that Tesamorelin produced significant reductions in visceral adipose tissue — measured by CT scan — compared to placebo, with accompanying improvements in triglyceride levels and other metabolic markers.
What makes Tesamorelin particularly interesting from a broader clinical perspective is what its mechanism reveals about the relationship between growth hormone secretagogues and visceral fat metabolism. Visceral adipose tissue has a higher density of growth hormone receptors than subcutaneous fat — making it specifically responsive to interventions that influence the growth hormone axis. This is the same visceral fat accumulation we discussed in the context of chronic cortisol elevation, and the convergence of these mechanisms is clinically meaningful.
Thymosin Alpha-1
Thymosin Alpha-1 is a naturally occurring peptide produced by the thymus gland — the organ responsible for the maturation of T-cells and the development of adaptive immune function.
It is approved for clinical use in multiple countries including Italy, China, and several Southeast Asian nations, and has been studied in human clinical trials across a range of immune-related conditions — including chronic hepatitis B and C, certain malignancies, and sepsis. Research has demonstrated its ability to enhance T-cell function, modulate the inflammatory response, and improve outcomes in contexts where immune function is compromised or dysregulated.
The mechanism operates through multiple pathways — increasing the expression of T-cell surface markers, enhancing natural killer cell activity, and modulating the production of pro-inflammatory and anti-inflammatory cytokines. A meta-analysis published in the International Immunopharmacology journal reviewed multiple randomized controlled trials of Thymosin Alpha-1 in chronic hepatitis B and found significant improvements in virological response compared to controls.
For the practitioner thinking about longevity and immune resilience — not acute disease management — Thymosin Alpha-1 represents one of the more compelling compounds in the evidence-based category. The relationship between thymic function, T-cell diversity, and biological aging is an active area of research, and the peptide's regulatory status in multiple jurisdictions provides a degree of clinical confidence that compounds in Categories Two and Three cannot offer.
GLP-1 Receptor Agonists
The GLP-1 receptor agonists — including semaglutide, liraglutide, and tirzepatide — represent the most rigorously studied peptide-based compounds in modern medicine, and they are almost certainly the category most people have encountered in recent public discourse.
GLP-1 — glucagon-like peptide-1 — is a naturally occurring incretin hormone produced in the gut in response to food intake. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and produces satiety signaling in the hypothalamus. GLP-1 receptor agonists are synthetic peptides that mimic and extend these effects — binding to the GLP-1 receptor with greater potency and duration than the endogenous hormone.
The evidence base for this class of compounds is substantial. Multiple large-scale randomized controlled trials have demonstrated meaningful improvements in glycemic control, body weight, cardiovascular outcomes, and more recently, metabolic and hepatic parameters. The SUSTAIN and LEADER trials for semaglutide and liraglutide respectively represent landmark studies in cardiovascular outcomes research. The SELECT trial, published in the New England Journal of Medicine in 2023, demonstrated that semaglutide produced a significant reduction in major adverse cardiovascular events in non-diabetic adults with overweight or obesity — an outcome with significant implications for longevity medicine.
I want to be precise about the clinical context here. The GLP-1 receptor agonists are powerful pharmacological tools with a well-established evidence base. They are also being used extensively outside their studied populations and without the clinical oversight their mechanism of action requires. The compound itself is not the conversation. The clinical appropriateness of its application — for whom, in what context, with what monitoring — is the conversation.
This distinction between the evidence for a compound and the appropriateness of its application in any individual case is a principle that applies across the entire peptide landscape. The evidence tells you what a compound can do under studied conditions. Clinical judgment tells you whether those conditions apply to the person in front of you.
What This Category Tells Us
The compounds in Category One share a common characteristic beyond their evidence base. They are all working with mechanisms the body already uses — stimulating endogenous hormone production, mimicking naturally occurring peptide signals, modulating immune pathways that the thymus was already managing.
This is the recurring theme of peptide science at its most defensible. The most clinically validated compounds are the ones that speak the body's language most clearly — that work with existing biological architecture rather than overriding it.
That principle does not validate every compound that claims to work this way. The body's language can be mimicked poorly as well as well. But it is a useful orienting framework for evaluating any compound in this space — and it is the framework I apply in my own clinical advisory work.
What Comes Next
Part 3 of this series moves into Category Two — the compounds where the animal data is compelling and the human research is early but directionally interesting.
This is where the clinical conversation requires more nuance and more caution — and where the distance between the community enthusiasm and the actual evidence base begins to widen.
That conversation is just as important as this one. Because understanding where the evidence is strong is only clinically useful if you also understand where it is not.
Work With Christopher Gabriel
If you are navigating the peptide space and want a clinical perspective grounded in the actual human evidence — this is precisely the advisory conversation we have at Life Science Performance.
The approach is systematic and science-driven, built around what the research actually shows and what is clinically appropriate for your specific biology, history, and goals.
If you are serious about approaching this with the rigor it deserves — that is where we start.
Christopher Gabriel is an integrative health practitioner, certified wellness counselor, and founder of Life Science Performance. His clinical work focuses on the intersection of nervous system regulation and nutritional optimization for high performers, professionals, and individuals committed to long-term health and performance.